# Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer

> **NCT04046445** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Amal Therapeutics** · enrollment: 96 (estimated)

## Conditions studied

- Colorectal Cancer
- MSS
- Stage IV Colon Cancer
- Stage IV Rectal Cancer
- Metastatic Colorectal Cancer
- Liver Metastasis Colon Cancer

## Interventions

- **DRUG:** ATP128
- **DRUG:** BI 754091
- **DRUG:** VSV-GP128

## Key facts

- **NCT ID:** NCT04046445
- **Lead sponsor:** Amal Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-07-22
- **Primary completion:** 2025-05-31
- **Final completion:** 2025-08-31
- **Target enrollment:** 96 (ESTIMATED)
- **Last updated:** 2025-01-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04046445

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04046445, "Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04046445. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*